1 |
Harvey K and Tapon N (2007) The Salvador-Warts-Hippo pathway - an emerging tumour-suppressor network. Nat Rev Cancer 7, 182-191
DOI
|
2 |
Meignin C, Alvarez-Garcia I, Davis I and Palacios IM (2007) The salvador-warts-hippo pathway is required for epithelial proliferation and axis specification in Drosophila. Curr Biol 17, 1871-1878
DOI
|
3 |
Zhang X, Milton CC, Humbert PO and Harvey KF (2009) Transcriptional output of the Salvador/warts/hippo pathway is controlled in distinct fashions in Drosophila melanogaster and mammalian cell lines. Cancer Res 69, 6033-6041
|
4 |
Huang J, Wu S, Barrera J, Matthews K and Pan D (2005) The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila Homolog of YAP. Cell 122, 421-434
DOI
|
5 |
Kango-Singh M and Singh A (2009) Singh, Regulation of organ size: insights from the Drosophila Hippo signaling pathway. Dev Dyn 238, 1627-1637
DOI
|
6 |
Pan D (2007) Hippo signaling in organ size control. Genes Dev 21, 886-897
DOI
|
7 |
Zhang L, Yue T and Jiang J (2009) Hippo signaling pathway and organ size control. Fly (Austin) 3, 68-73
DOI
|
8 |
Wang K, Degerny C, Xu M and Yang XJ (2009) YAP, TAZ, and Yorkie: a conserved family of signal-responsive transcriptional coregulators in animal development and human disease. Biochem Cell Biol 87, 77-91
DOI
|
9 |
Kim HB, Kim M, Park YS et al (2017) Prostaglandin E2 Activates YAP and a Positive-Signaling Loop to Promote Colon Regeneration After Colitis but Also Carcinogenesis in Mice. Gastroenterology 152, 616-630
DOI
|
10 |
Zhang L and Yu J (2013) Role of apoptosis in colon cancer biology, therapy, and prevention. Curr Colorectal Cancer Rep 9
|
11 |
Udan RS, Kango-Singh M, Nolo R, Tao C and Halder G (2003) Hippo promotes proliferation arrest and apoptosis in the Salvador/Warts pathway. Nat Cell Biol 5, 914-920
DOI
|
12 |
Xu T, Wang W, Zhang S, Stewart RA and Yu W (1995) Identifying tumor suppressors in genetic mosaics: the Drosophila lats gene encodes a putative protein kinase. Development 121, 1053-1063
|
13 |
Pantalacci S, Tapon N and Leopold P (2003) The Salvador partner Hippo promotes apoptosis and cell-cycle exit in Drosophila. Nat Cell Biol 5, 921-927
DOI
|
14 |
Jia J, Zhang W, Wang B, Trinko R and Jiang J (2003) The Drosophila Ste20 family kinase dMST functions as a tumor suppressor by restricting cell proliferation and promoting apoptosis. Genes Dev 17, 2514-2519
DOI
|
15 |
Piccolo S, Dupont S and Cordenonsi M (2014) The biology of YAP/TAZ: hippo signaling and beyond. Physiol Rev 94, 1287-1312
DOI
|
16 |
Harvey KF, Zhang X and Thomas DM (2013) Thomas, The Hippo pathway and human cancer. Nat Rev Cancer 13, 246-257
DOI
|
17 |
Yu FX, Zhao B and Guan KL (2015) Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer. Cell 163, 811-828
DOI
|
18 |
Piccolo S, Cordenonsi M and Dupont S (2013) Molecular pathways: YAP and TAZ take center stage in organ growth and tumorigenesis. Clin Cancer Res 19, 4925-4930
DOI
|
19 |
Lee KW, Lee SS, Kim SB et al (2015) Significant association of oncogene YAP1 with poor prognosis and cetuximab resistance in colorectal cancer patients. Clin Cancer Res 21, 357-364
DOI
|
20 |
Ling HH, Kuo CC, Lin BX, Huang YH and Lin CW (2017) Elevation of YAP promotes the epithelial-mesenchymal transition and tumor aggressiveness in colorectal cancer. Exp Cell Res 350, 218-225
DOI
|
21 |
Jerhammar F, Johansson AC, Ceder R et al (2014) YAP1 is a potential biomarker for cetuximab resistance in head and neck cancer. Oral Oncol 50, 832-839
DOI
|
22 |
Hernanda PY, Pedroza-Gonzalez A, Sprengers D, Peppelenbosch MP and Pan Q (2014) Multipotent mesenchymal stromal cells in liver cancer: implications for tumor biology and therapy. Biochim Biophys Acta 1846, 439-445
|
23 |
Kudo M (2012) Targeted therapy for liver cancer: updated review in 2012. Curr Cancer Drug Targets 12, 1062-1072
|
24 |
Oishi N, Yamashita T and Kaneko S (2014) Molecular biology of liver cancer stem cells. Liver Cancer 3, 71-84
DOI
|
25 |
Kim Y and Jho EH (2017) Deubiquitinase YOD1: the potent activator of YAP in hepatomegaly and liver cancer. BMB Rep 50, 281-282
DOI
|
26 |
Liu AM, Xu MZ, Chen J, Poon RT and Luk JM (2010) Targeting YAP and Hippo signaling pathway in liver cancer. Expert Opin Ther Targets 14, 855-868
DOI
|
27 |
Liu AM, Xu Z and Luk JM (2012) An update on targeting Hippo-YAP signaling in liver cancer. Expert Opin Ther Targets 16, 243-247
DOI
|
28 |
Steinhardt AA, Gayyed MF, Klein AP et al (2008) Expression of Yes-associated protein in common solid tumors. Hum Pathol 39, 1582-1589
DOI
|
29 |
Keren-Paz A, Emmanuel R and Samuels Y (2015) YAP and the drug resistance highway. Nat Genet 47, 193-194
DOI
|
30 |
Jiao S, Wang H and Shi Z (2014) A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer. Cancer Cell 25, 166-180
DOI
|
31 |
Zhao B, Ye X, Yu J et al (2008) TEAD mediates YAP-dependent gene induction and growth control. Genes Dev 22, 1962-1971
DOI
|
32 |
Camargo FD, Gokhale S, Johnnidis JB et al (2007) YAP1 increases organ size and expands undifferentiated progenitor cells. Curr Biol 17, 2054-2060
DOI
|
33 |
Chan EH, Nousiainen M, Chalamalasetty RB, Schafer A, Nigg EA and Sillje HH (2005) The Ste20-like kinase Mst2 activates the human large tumor suppressor kinase Lats1. Oncogene 24, 2076-2086
DOI
|
34 |
Hao Y, Chun A, Cheung K, Rashidi B and Yang X (2008) Tumor suppressor LATS1 is a negative regulator of oncogene YAP. J Biol Chem 283, 5496-5509
DOI
|
35 |
Flaherty KT, Hodi FS and Fisher DE (2012) From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer 12, 349-361
DOI
|
36 |
Eggermont AM and Robert C (2012) Melanoma in 2011: a new paradigm tumor for drug development. Nat Rev Clin Oncol 9, 74-76
DOI
|
37 |
Jones PS and Jones D (2012) New regulatory framework for cancer drug development. Drug Discov Today 17, 227-231
DOI
|
38 |
Mullard A (2015) The Roadmap Epigenomics Project opens new drug development avenues. Nat Rev Drug Discov 14, 223-225
DOI
|
39 |
Wang Y, Xie C, Li Q, Xu K and Wang E (2013) Clinical and prognostic significance of Yes-associated protein in colorectal cancer. Tumour Biol 34, 2169-2174
DOI
|
40 |
Vukicevic S (2016) Current Challenges and Hurdles in New Drug Development. Clin Ther 38, e3
|
41 |
De Angelis ML, De Maria R and Baiocchi M (2018) How to Assess Drug Resistance in Cancer Stem Cells. Methods Mol Biol 1692, 107-115
|
42 |
Emery CM, Vijayendran KG, Zipser MC et al (2009) MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A 106, 20411-20416
DOI
|
43 |
Cervantes A, Rodriguez Braun E, Perez Fidalgo A and Chirivella Gonzalez I (2007) Molecular biology of gastric cancer. Clin Transl Oncol 9, 208-215
DOI
|
44 |
Liu-Chittenden Y, Huang B, Shim JS et al (2012) Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev 26, 1300-1305
DOI
|
45 |
Yimlamai D, Fowl BH and Camargo FD (2015) Emerging evidence on the role of the Hippo/YAP pathway in liver physiology and cancer. J Hepatol 63, 1491-1501
DOI
|
46 |
Han SX, Bai E, Jin GH et al (2014) Expression and clinical significance of YAP, TAZ, and AREG in hepatocellular carcinoma. J Immunol Res 2014, 261365
|
47 |
Dreznik A, Purim O, Idelevich E et al (2012) Gastric cancer: biology and clinical manifestations in Israel. J Surg Oncol 105, 316-322
DOI
|
48 |
El-Rifai W and Powell SM (2002) Molecular biology of gastric cancer. Semin Radiat Oncol 12, 128-140
DOI
|
49 |
Cai J, Zhang N, Zheng Y, de Wilde RF, Maitra A and Pan D (2010) The Hippo signaling pathway restricts the oncogenic potential of an intestinal regeneration program. Genes Dev 24, 2383-2388
DOI
|
50 |
Zhou D, Zhang Y, Wu H et al (2011) Mst1 and Mst2 protein kinases restrain intestinal stem cell proliferation and colonic tumorigenesis by inhibition of Yes-associated protein (Yap) overabundance. Proc Natl Acad Sci U S A 108, E1312- E1320
DOI
|
51 |
Kaan HYK, Chan SW, Tan SKJ et al (2017) Crystal structure of TAZ-TEAD complex reveals a distinct interaction mode from that of YAP-TEAD complex. Sci Rep 7, 2035
DOI
|
52 |
Mansoori B, Mohammadi A, Davudian S, Shirjang S and Baradaran B (2017) The Different Mechanisms of Cancer Drug Resistance: A Brief Review. Adv Pharm Bull 7, 339-348
DOI
|
53 |
Guang MHZ, McCann A, Bianchi G et al (2018) Overcoming multiple myeloma drug resistance in the era of cancer 'omics'. Leuk Lymphoma 59, 542-561
DOI
|
54 |
Norouzi-Barough L, Sarookhani MR, Sharifi M, Moghbelinejad S, Jangjoo S and Salehi R (2017) Molecular Mechanisms of Drug Resistance in Ovarian Cancer. J Cell Physiol [Epub ahead of print]
|
55 |
Siegfried Z and Karni R (2017) The role of alternative splicing in cancer drug resistance. Curr Opin Genet Dev 48, 16-21
|
56 |
Lin CH, Pelissier FA, Zhang H et al (2015) Microenvironment rigidity modulates responses to the HER2 receptor tyrosine kinase inhibitor lapatinib via YAP and TAZ transcription factors. Mol Biol Cell 26, 3946-3953
DOI
|
57 |
Moroishi T, Hansen CG and Guan KL (2015) The emerging roles of YAP and TAZ in cancer. Nat Rev Cancer 15, 73-79
DOI
|
58 |
Zhang Z, Lin Z, Zhou Z et al (2014) Structure-Based Design and Synthesis of Potent Cyclic Peptides Inhibiting the YAP-TEAD Protein-Protein Interaction. ACS Med Chem Lett 5, 993-998
DOI
|
59 |
Lin L, Sabnis AJ, Chan E et al (2015) The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nat Genet 47, 250-256
DOI
|
60 |
Guo L and Teng L (2015) YAP/TAZ for cancer therapy: opportunities and challenges (review). Int J Oncol 46, 1444-1452
DOI
|
61 |
Ma Y, Yang Y, Wang F, Wei Q and Qin H (2015) Hippo-YAP signaling pathway: A new paradigm for cancer therapy. Int J Cancer 137, 2275-2286
DOI
|
62 |
Kim MH, Kim J, Hong H et al (2016) Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP/TAZ activation. EMBO J 35, 462-478
DOI
|
63 |
Hsu PC, You B, Yang YL et al (2016) YAP promotes erlotinib resistance in human non-small cell lung cancer cells. Oncotarget 7, 51922-51933
|
64 |
Sun PL, Jin Y and Chung JH (2017) Reply: YAP is a Key Factor to Improve the Management of Cancer Treatments. Ann Surg Oncol 24, 644-645
DOI
|
65 |
Zanconato F, Battilana G, Cordenonsi M and Piccolo S (2016) YAP/TAZ as therapeutic targets in cancer. Curr Opin Pharmacol 29, 26-33
DOI
|
66 |
Andl T, Zhou L, Yang K, Kadekaro AL and Zhang Y (2017) YAP and WWTR1: New targets for skin cancer treatment. Cancer Lett 396, 30-41
DOI
|
67 |
Kim MH and Kim J (2017) Role of YAP/TAZ transcriptional regulators in resistance to anti-cancer therapies. Cell Mol Life Sci 74, 1457-1474
DOI
|
68 |
Avril T and Chevet E (2015) Proteostasis trumps YAP in colon cancer. Sci Signal 8, fs18
DOI
|
69 |
Zhang Y, Shen H, Withers HG et al (2017) VGLL4 Selectively Represses YAP-Dependent Gene Induction and Tumorigenic Phenotypes in Breast Cancer. Sci Rep 7, 6190
DOI
|
70 |
Ahmed AA, Mohamed AD, Gener M, Li W and Taboada E (2017) YAP and the Hippo pathway in pediatric cancer. Mol Cell Oncol 4, e1295127
DOI
|
71 |
Cao L, Sun PL, Yao M, Jia M and Gao H (2017) Expression of YES-associated protein (YAP) and its clinical significance in breast cancer tissues. Hum Pathol 68, 166-174
DOI
|
72 |
Eibl G and Rozengurt E (2017) YAP, and obesity in pancreatic cancer: A signaling network with multiple loops. Semin Cancer Biol [Epub ahead of print]
|
73 |
Feng J, Gou J, Jia J, Yi T, Cui T and Li Z (2016) Verteporfin, a suppressor of YAP-TEAD complex, presents promising antitumor properties on ovarian cancer. Onco Targets Ther 9, 5371-5381
DOI
|
74 |
Kim HM, Jung WH and Koo JS (2015) Expression of Yes-associated protein (YAP) in metastatic breast cancer. Int J Clin Exp Pathol 8, 11248-11257
|
75 |
Lemjabbar-Alaoui H, Hassan OU, Yang YW and Buchanan P (2015) Lung cancer: Biology and treatment options. Biochim Biophys Acta 1856, 189-210
|
76 |
Zanconato F, Cordenonsi M and Piccolo S (2016) YAP/TAZ at the Roots of Cancer. Cancer Cell 29, 783-803
DOI
|
77 |
Zhou GX, Li XY, Zhang Q et al (2013) Effects of the hippo signaling pathway in human gastric cancer. Asian Pac J Cancer Prev 14, 5199-5205
DOI
|
78 |
Formisano L, Jansen VM, Marciano R and Bianco R (2017) From biology to therapy: Improvements of therapeutic options in Lung cancer. Anticancer Agents Med Chem [Epub ahead of print]
|
79 |
Suda K and Mitsudomi T (2017) [Molecular Biology for Surgical Treatment of Lung Cancer]. Kyobu Geka 70, 4-8
|
80 |
Lee BS, Park DI, Lee DH et al (2017) Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma. Biochem Biophys Res Commun 491, 493-499
DOI
|
81 |
Lee JE, Park HS, Lee D et al (2016) Hippo pathway effector YAP inhibition restores the sensitivity of EGFR-TKI in lung adenocarcinoma having primary or acquired EGFR-TKI resistance. Biochem Biophys Res Commun 474, 154-160
DOI
|
82 |
Cordenonsi M, Zanconato F, Azzolin L et al (2011) The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell 147, 759-772
DOI
|
83 |
Karachaliou N, Chaib I, Pilotto S et al (2016) 76P An innovative co-targeting of signal transducer and activator of transcription 3 (STAT3) and Src-YAP pathways in EGFR mutant non-small cell lung cancer (NSCLC). J Thorac Oncol 11, S87-S88
|
84 |
Wang H, Lu B, Castillo J et al (2016) Tankyrase Inhibitor Sensitizes Lung Cancer Cells to Endothelial Growth Factor Receptor (EGFR) Inhibition via Stabilizing Angiomotins and Inhibiting YAP Signaling. J Biol Chem 291, 15256-15266
DOI
|
85 |
Maugeri-Sacca M, Barba M, Pizzuti L et al (2015) The Hippo transducers TAZ and YAP in breast cancer: oncogenic activities and clinical implications. Expert Rev Mol Med 17, e14
DOI
|
86 |
Parsa Y, Mirmalek SA, Kani FE et al (2016) A Review of the Clinical Implications of Breast Cancer Biology. Electron Physician 8, 2416-2424
DOI
|
87 |
Chan SW, Lim CJ, Guo K et al (2008) A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. Cancer Res 68, 2592-2598
DOI
|
88 |
Diaz-Martin J, Lopez-Garcia MA, Romero-Perez L et al (2015) Nuclear TAZ expression associates with the triple-negative phenotype in breast cancer. Endocr Relat Cancer 22, 443-454
DOI
|
89 |
Bartucci M, Dattilo R, Moriconi C et al (2015) TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells. Oncogene 34, 681-690
DOI
|
90 |
Li YW, Shen H, Frangou C et al (2015) Characterization of TAZ domains important for the induction of breast cancer stem cell properties and tumorigenesis. Cell Cycle 14, 146-156
DOI
|
91 |
Yuan M, Tomlinson V, Lara R et al (2008) Yes-associated protein (YAP) functions as a tumor suppressor in breast. Cell Death Differ 15, 1752-1759
DOI
|
92 |
Kim SK, Jung WH and Koo JS (2014) Yes-associated protein (YAP) is differentially expressed in tumor and stroma according to the molecular subtype of breast cancer. Int J Clin Exp Pathol 7, 3224-3234
|
93 |
Jaramillo-Rodriguez Y, Cerda-Flores RM, Ruiz-Ramos R, Lopez-Marquez FC and Calderon-Garciduenas AL (2014) YAP expression in normal and neoplastic breast tissue: an immunohistochemical study. Arch Med Res 45, 223-228
DOI
|
94 |
Kagawa Y, Ishii H, Sekimoto M, Doki Y and Mori M (2011) [Molecular biology of colon cancer]. Nihon Rinsho 69, 67-71
|